NCI-2024-03452

A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy in Adult Subjects with Advanced Solid Tumors with MAPK Pathway Mutations.

This is a Phase 1 research study where researchers are testing a new drug called D3S-002 on adults who have advanced solid tumors. The study is "open-label," meaning both the researchers and the participants know which treatment is being administered. The specific focus is on adults who have solid tumors that contain mutations in the MAPK pathway. This pathway is important because it regulates cell growth and division, and mutations can contribute to cancer development. The researchers want to see if D3S-002 can be effective against these tumors and learn more about how it works in the body.

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05886920

Clinical Trial Site: Sinai

To see all available clinical trials click here.